Elevance Health (ELV) has released its Q2 2026 numbers, reporting revenue of about US$50.5b, basic EPS of US$6.71 and net income of US$1,463m. The trailing twelve months show revenue of roughly US$201.1b, EPS of US$22.53 and net income of US$4,963m. Over recent quarters the company has seen revenue move from US$49.8b in Q2 2025 to US$50.5b in Q2 2026. Over the same period, quarterly basic EPS shifted from US$7.74 to US$6.71 and net income from US$1,743m to US$1,463m, setting the backdrop for how investors weigh the latest results against slightly softer profit margins.
See our full analysis for Elevance Health.With the headline numbers on the table, the next step is to see how this earnings profile lines up with the prevailing narratives about Elevance Health's growth potential, risks and profitability drivers.
See what the community is saying about Elevance Health
Margins Under Pressure at 2.5%
- Trailing net profit margin sits at 2.5%, compared with 2.8% a year earlier, while trailing twelve month net income is about US$5.0b on revenue of roughly US$201.1b.
- Bears argue that elevated medical costs in areas like Medicaid and ACA plans could keep squeezing Elevance Health's margins. The dip from a 2.8% to 2.5% trailing margin lines up with that concern, even though quarterly revenue has hovered around US$50b and Q2 2026 net income of US$1.5b is still sizeable for funding technology and integration spending.
- The cautious narrative also points to five year earnings declining about 0.6% a year, which fits with trailing twelve month net income moving from about US$5.9b to roughly US$5.0b in the data.
- At the same time, Q2 2026 EPS of US$6.71 and Q1 2026 EPS of US$8.03 show that profitability remains meaningful in absolute terms, which may help offset some of the long term margin worries if cost trends stabilise.
Forecast 13.9% Earnings Growth vs 2% Revenue
- The dataset shows revenue forecast growth of about 2% a year while earnings are forecast to grow roughly 13.9% a year. This suggests a wider gap between top line expansion and projected profit growth than recent trailing trends where net income is about US$5.0b on US$201.1b of revenue.
- Supporters of the bullish narrative point to value based care, AI driven efficiencies, and growth in Carelon and government segments as reasons earnings could outpace revenue. The 13.9% forecast earnings growth contrasts with the modest 2% revenue forecast and current 2.5% margin, so investors watching Elevance Health may treat those efficiency claims as key to whether this spread actually shows up in future reported numbers.
- Forecast revenue growth of about 2% per year is not far from the trailing revenue step up from roughly US$189.3b to US$201.1b, which means much of the bullish case rests on margins improving from the current 2.5% level rather than sales accelerating dramatically.
- The bullish view also assumes margins can move from about 2.6% to above 3% over time, so the recent shift from 2.8% to 2.5% trailing margin gives you a concrete starting point to judge whether those expectations look ambitious or reasonable as new quarters come in.
Valuation Discount vs P/E 16.3x
- With the share price at US$372.85 and a P/E of 16.3x, Elevance Health trades below the US Healthcare industry average P/E of 25.1x and a peer average of 42.8x. A DCF fair value in the data of about US$1,202.25 suggests a large gap to that model and analysts are using an allowed price target of US$447.62.
- Consensus narrative suggests this lower P/E, combined with a 1.85% dividend yield and forecast 13.9% earnings growth, may reflect investor caution around slower 2% revenue forecasts and the 2.5% trailing margin. The key question for readers is whether the mix of a valuation discount and modest top line outlook fairly reflects the risks around cost trends and government exposure highlighted in both bullish and bearish commentary.
- The DCF fair value of roughly US$1,202.25 is far above the current US$372.85 price, which heavily supports the argument that the market is applying a sizeable safety margin despite forecast earnings growth and a dividend yield of 1.85%.
- At the same time, the 2% revenue growth forecast and five year earnings decline of about 0.6% a year help explain why the market might be reluctant to pay industry like multiples until there is clearer evidence that the earnings growth path is tracking closer to the 13.9% forecast.
Next Steps
To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Elevance Health on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.
Sentiment across Elevance Health's latest numbers is mixed, so it makes sense to move quickly and test the narrative against the underlying figures yourself. For a clearer view of what the market is already optimistic about, take a closer look at the 5 key rewards
See What Else Is Out There
Elevance Health's story includes a 2.5% trailing margin, softer earnings trends and modest 2% revenue forecasts, which together highlight pressure on profitability and growth.
If those margin strains and slower earnings forecasts leave you wanting sturdier profit profiles, check out companies in the 82 resilient stocks with low risk scores that emphasise resilience and consistency.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com